Active Ingredient History
Cyclobenzaprine is a centrally-acting muscle relaxant which boosts levels of norepinephrine and binds to serotonin receptors in the brain to reduce spasm. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Drowsiness, fatigue and sedation (up to 40%) is the most common side effect of Cyclobenzaprine. It may have life-threatening interactions with monoamine oxidase (MAO) inhibitors. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Musculoskeletal Diseases (approved 1988)
Acute Pain (Phase 4)
Automobile Driving (Phase 1)
Back Injuries (Phase 3)
Back Pain (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
COVID-19 (Phase 2)
Depression (Phase 1)
Fatigue (Phase 4)
Fibromyalgia (Phase 4)
Healthy Volunteers (Phase 1)
Liver Cirrhosis (Phase 3)
Low Back Pain (Phase 3)
Melanoma (Phase 1/Phase 2)
Migraine Disorders (Phase 3)
Muscular Diseases (Phase 3)
Musculoskeletal Diseases (Phase 3)
Musculoskeletal Pain (Phase 3)
Myofascial Pain Syndromes (Phase 3)
Neck Pain (Phase 3)
Neoplasms (Phase 1)
Nervous System Diseases (Phase 3)
Neuromuscular Diseases (Phase 3)
Pain (Phase 4)
Post-Acute COVID-19 Syndrome (Phase 2)
Rheumatic Diseases (Phase 3)
Sciatica (Phase 3)
Sleep (Phase 4)
Spasm (Phase 4)
Sprains and Strains (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
Stress Disorders, Post-Traumatic (Phase 3)
Tooth (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
